TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis
Brief Summary: The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing over the birch pollen season compared with placebo for reduction of rhinoconjunctivitis-related symptoms and anti-allergy medication usage.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Intervention Type: BIOLOGICAL; Name: Recombinant birch pollen; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MK-8237 6 Developmental Units (DU); Type: EXPERIMENTAL; Interventions: Drug: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Drug: MK-8237 12 DU | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 Developmental Units (DU) | Intervention Type: DRUG; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Birch pollen allergen extract; Type: EXPERIMENTAL; Interventions: Biological: Birch pollen allergen extract | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Birch pollen allergen extract; Assigned to Arm(s): Birch pollen allergen extract

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Narrative Exposure Therapy (NET) in a Sample of Iranian Women Exposed to Intimate Partner Violence (IPV)
Brief Summary: The proposed study seeks to investigate to what extent Narrative Exposure Therapy (NET) is an effective treatment for the reduction of symptoms of Post-Traumatic Stress Disorder (PTSD) and depression and for the improvement of daily functioning in Iranian women who have experienced intimate partner violence (IPV). In addition, the study seeks to investigate whether NET therapy could lead to the reduction of Intimate Partner Violence (IPV) within their marriage.


Options:
A: Arm Label: Qigong training; Type: EXPERIMENTAL; Interventions: Behavioral: Qigong training | Arm Label: Wait-list control- Health talks; Type: OTHER; Interventions: Other: Wait-list control- Health talks | Intervention Type: BEHAVIORAL; Name: Qigong training; Assigned to Arm(s): Qigong training | Intervention Type: OTHER; Name: Wait-list control- Health talks; Assigned to Arm(s): Wait-list control- Health talks
B: Arm Label: Treamtent-as-usual; Type: OTHER; Interventions: Other: Treatment-as-usual | Arm Label: Narrative Exposure Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): Narrative Exposure Therapy | Intervention Type: OTHER; Name: Treatment-as-usual; Assigned to Arm(s): Treamtent-as-usual
C: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
D: Arm Label: ROSE Program; Type: EXPERIMENTAL; Interventions: Behavioral: ROSE Program | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ROSE Program; Assigned to Arm(s): ROSE Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Narrative Exposure Therapy (NET) in a Sample of Iranian Women Exposed to Intimate Partner Violence (IPV)
Brief Summary: The proposed study seeks to investigate to what extent Narrative Exposure Therapy (NET) is an effective treatment for the reduction of symptoms of Post-Traumatic Stress Disorder (PTSD) and depression and for the improvement of daily functioning in Iranian women who have experienced intimate partner violence (IPV). In addition, the study seeks to investigate whether NET therapy could lead to the reduction of Intimate Partner Violence (IPV) within their marriage.


Options:
A: Arm Label: STAIR stands for Skills Training in Affective and Interpersonal Regulation; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training in Affective and Interpersonal Regulation | Arm Label: Present Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present Centered Therapy | Intervention Type: BEHAVIORAL; Name: Skills Training in Affective and Interpersonal Regulation; Assigned to Arm(s): STAIR stands for Skills Training in Affective and Interpersonal Regulation | Intervention Type: BEHAVIORAL; Name: Present Centered Therapy; Assigned to Arm(s): Present Centered Therapy
B: Arm Label: PE-HBT; Type: EXPERIMENTAL; Interventions: Behavioral: PE | Arm Label: PE-SD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PE | Intervention Type: BEHAVIORAL; Name: PE; Assigned to Arm(s): PE-HBT, PE-SD
C: Arm Label: Treamtent-as-usual; Type: OTHER; Interventions: Other: Treatment-as-usual | Arm Label: Narrative Exposure Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): Narrative Exposure Therapy | Intervention Type: OTHER; Name: Treatment-as-usual; Assigned to Arm(s): Treamtent-as-usual
D: Arm Label: ROSE Program; Type: EXPERIMENTAL; Interventions: Behavioral: ROSE Program | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ROSE Program; Assigned to Arm(s): ROSE Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Communication and Health for Adolescents With Technology - Implementation of Immunization Strategy
Brief Summary: The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age. This is a 3-dose series and many adolescents do not complete it after getting the first dose. This study will study how effective it will be to send reminders to parents to schedule an appointment when their child is due for the next dose of HPV. Parents can chose whether they would like a phone call or text message reminder. This study will determine if the reminders work, and if one method is better than another (phone message vs. text message).


Options:
A: Arm Label: Control, standard care for HPV vaccine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention, computer reminder system; Type: EXPERIMENTAL; Interventions: Behavioral: Computer reminder system | Intervention Type: BEHAVIORAL; Name: Computer reminder system; Assigned to Arm(s): Intervention, computer reminder system
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: "COMBINED STRATEGY" | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: "COMBINED STRATEGY"; Assigned to Arm(s): Intervention group
C: Arm Label: Telephone reminder; Type: EXPERIMENTAL; Interventions: Other: Telephone reminder | Arm Label: Text Message reminder; Type: EXPERIMENTAL; Interventions: Other: Text Message reminder | Arm Label: Control: Telephone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control: Text Message; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone reminder; Assigned to Arm(s): Telephone reminder | Intervention Type: OTHER; Name: Text Message reminder; Assigned to Arm(s): Text Message reminder
D: Arm Label: Lay Health Worker Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay Health Worker Intervention | Arm Label: Placebo (a list of resources); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo (a list of resources) | Intervention Type: BEHAVIORAL; Name: Lay Health Worker Intervention; Assigned to Arm(s): Lay Health Worker Intervention | Intervention Type: BEHAVIORAL; Name: Placebo (a list of resources); Assigned to Arm(s): Placebo (a list of resources)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Communication and Health for Adolescents With Technology - Implementation of Immunization Strategy
Brief Summary: The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age. This is a 3-dose series and many adolescents do not complete it after getting the first dose. This study will study how effective it will be to send reminders to parents to schedule an appointment when their child is due for the next dose of HPV. Parents can chose whether they would like a phone call or text message reminder. This study will determine if the reminders work, and if one method is better than another (phone message vs. text message).


Options:
A: Arm Label: The Cedar Project mHealth Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The Cedar Project mHealth intervention | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Cedar Project mHealth intervention; Assigned to Arm(s): The Cedar Project mHealth Intervention
B: Arm Label: Telephone reminder; Type: EXPERIMENTAL; Interventions: Other: Telephone reminder | Arm Label: Text Message reminder; Type: EXPERIMENTAL; Interventions: Other: Text Message reminder | Arm Label: Control: Telephone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control: Text Message; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone reminder; Assigned to Arm(s): Telephone reminder | Intervention Type: OTHER; Name: Text Message reminder; Assigned to Arm(s): Text Message reminder
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Contraceptive text messages | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Text messages not about contraception | Intervention Type: BEHAVIORAL; Name: Contraceptive text messages; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Text messages not about contraception; Assigned to Arm(s): Control
D: Arm Label: Two-way SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Two-way SMS | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two-way SMS; Assigned to Arm(s): Two-way SMS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II
Brief Summary: The aim of this study is to assess the efficacy of a rituximab regimen based on rate of ANCA and CD19 lymphocytes for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized comparative study of two rituximab regimens: one based on ANCA and CD19 lymphocytes versus systematic infusions.


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group), Drug: Methylprednisolone (or other glucocorticoid), Drug: Prednisone | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide plus rituximab placebo (control group), Drug: Azathioprine, Drug: Methylprednisolone (or other glucocorticoid), Drug: Prednisone | Intervention Type: DRUG; Name: Rituximab plus cyclophosphamide placebo (rituximab group); Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide plus rituximab placebo (control group); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Methylprednisolone (or other glucocorticoid); Assigned to Arm(s): Control Group, Rituximab | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Control Group, Rituximab
B: Arm Label: Placebo plus azathioprine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Azathioprine | Arm Label: Belimumab 10 mg/kg plus azathioprine; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus azathioprine | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine, Placebo plus azathioprine
C: N/A
D: Arm Label: Rituximab infusion according biological parameters; Type: EXPERIMENTAL; Interventions: Drug: Rituximab (Arm B) | Arm Label: Systematic rituximab infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab (Arm A) | Intervention Type: DRUG; Name: Rituximab (Arm B); Assigned to Arm(s): Rituximab infusion according biological parameters | Intervention Type: DRUG; Name: Rituximab (Arm A); Assigned to Arm(s): Systematic rituximab infusion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome
Brief Summary: BACKGROUND: Currently, there is no proven pharmacologic treatment for patients with the acute respiratory distress syndrome (ARDS). Great interest remains in the use of corticosteroids for the salvage of patients with severe acute lung injury in the early phase of their disease process, a situation that that has not been evaluated in most published trials. Dexamethasone has never been evaluated in ARDS in a randomized controlled fashion.

HYPOTHESIS AND OBJECTIVES: The investigators hypothesize that adjunctive treatment with intravenous dexamethasone of patients with established ARDS might change the pulmonary and systemic inflammatory response and thereby will increase the number of ventilator-free days and will decrease the extremely high overall mortality. Our goal is to examine the effects of dexamethasone on length of duration of mechanical ventilation (assessed by number of ventilator-free days) and on mortality, in patients admitted into a network of Spanish intensive care units (ICUs) who still meet ARDS criteria at 24 hours after ARDS onset.


Options:
A: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: No dexamethasone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone
C: Arm Label: AP301; Type: EXPERIMENTAL; Interventions: Drug: AP301 | Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Intervention Type: DRUG; Name: AP301; Assigned to Arm(s): AP301 | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): saline solution
D: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy
Brief Summary: Pancreaticojejunostomy is the key procedure of pancreaticoduodenectomy. The aim of our study is to investigate a new pancreaticojejunal (PJ) anastomosis procedure named "nonstented stump-closed pancreaticojejunostomy" in pancreatoduodenectomy, which could provide a feasible option to pancreatic surgeons for patients with pancreaticoduodenectomy.


Options:
A: Arm Label: one-layer duct-to-mucosa anastomosis; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Arm Label: two-layer duct-to-mucosa anastomosis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): one-layer duct-to-mucosa anastomosis, two-layer duct-to-mucosa anastomosis
B: Arm Label: Duct to mucosa PJ group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Duct to mucosa PJ group | Arm Label: Invagination PJ group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Invagination PJ group | Intervention Type: PROCEDURE; Name: Duct to mucosa PJ group; Assigned to Arm(s): Duct to mucosa PJ group | Intervention Type: PROCEDURE; Name: Invagination PJ group; Assigned to Arm(s): Invagination PJ group
C: Arm Label: Nonstented stump-closed anastomosis; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Arm Label: Duct-to-mucosa anastomosis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): Duct-to-mucosa anastomosis, Nonstented stump-closed anastomosis
D: Arm Label: One-layer duct-to-mucosa Group; Type: EXPERIMENTAL; Interventions: Procedure: Modified one-layer duct-to-mucosa Pancreaticojejunostomy | Arm Label: Invagination Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Invagination pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: Modified one-layer duct-to-mucosa Pancreaticojejunostomy; Assigned to Arm(s): One-layer duct-to-mucosa Group | Intervention Type: PROCEDURE; Name: Invagination pancreaticojejunostomy; Assigned to Arm(s): Invagination Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem
Brief Summary: The purpose of this study is to determine whether the addition of meropenem to colistin is better than colistin alone in the treatment of clinically significant infections caused by multi-drug resistant bacteria


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Arm Label: Amoxicillin 45mg/kg 12 hourly; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin | Arm Label: Benzyl Penicillin 50,000IU/kg 6 hourly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benzyl penicillin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin 45mg/kg 12 hourly | Intervention Type: DRUG; Name: Benzyl penicillin; Assigned to Arm(s): Benzyl Penicillin 50,000IU/kg 6 hourly
C: Arm Label: Colistin and Meropenem; Type: EXPERIMENTAL; Interventions: Drug: Colistin, Drug: Meropenem | Arm Label: Colistin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colistin | Intervention Type: DRUG; Name: Colistin; Assigned to Arm(s): Colistin, Colistin and Meropenem | Intervention Type: DRUG; Name: Meropenem; Assigned to Arm(s): Colistin and Meropenem
D: Arm Label: Ceftobiprole medocaril; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole medocaril | Arm Label: IV standard-of-care cephalosporin; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV standard-of-care cephalosporin | Intervention Type: DRUG; Name: ceftobiprole medocaril; Assigned to Arm(s): Ceftobiprole medocaril | Intervention Type: DRUG; Name: IV standard-of-care cephalosporin; Assigned to Arm(s): IV standard-of-care cephalosporin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium Plus Vitamin D Supplementation During Pregnancy of Adolescent Mothers: Effects on Maternal and Infant Bone Mass, Calcium and Bone Metabolism and Breast Milk Composition
Brief Summary: Pregnancy and lactation are periods of high calcium requirement. Inadequate maternal calcium intake and vitamin D insufficiency may adversely affect fetal and neonatal growth and maternal bone mass particularly in adolescent mothers. The investigators propose to evaluate the influence of calcium plus vitamin D supplementation during pregnancy on bone mass of lactating adolescent mothers with habitually low calcium and vitamin D, on fetal growth and neonate bone mass. Mothers are randomly assigned to receive daily calcium (600 mg) plus vitamin D3 (200 IU) supplement or placebo from mid gestation until parturition. Fetal growth parameters are assessed by standard ultrasound techniques at mid and late gestation. Maternal bone mass is assessed by dual energy x-ray absorptiometry (DXA) at 2 and 5 months postpartum and 6 months after weaning. Infant bone mass is assessed by DXA at 2 months postpartum.


Options:
A: Intervention Type: OTHER; Name: Blood and breastmilk samples; Assigned to Arm(s): N/A
B: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained
C: Arm Label: 400 IU Vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol (D3) or ergocalciferol (D2) | Arm Label: 400 IU Vitamin D2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (D3) or ergocalciferol (D2) | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (D3) or ergocalciferol (D2); Assigned to Arm(s): 400 IU Vitamin D2, 400 IU Vitamin D3
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Calcium plus vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Calcium plus vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium plus vitamin D; Assigned to Arm(s): Calcium plus vitamin D

Answer: D